---
title: "这家医药企业纳斯达克上市：首日大涨39% 市值10亿美元 路演PPT曝光"
date: "2025-02-08 11:37:36"
summary: "雷递网 雷建平 2月8日Sionna Therapeutics（股票代码为：“SION” ）昨天在美..."
categories:
  - "leinews"
lang:
  - "zh-CN"
translations:
  - "zh-CN"
tags:
  - "leinews"
menu: ""
thumbnail: "https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250208/6387461145175547948319510.jpeg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![](https://p3-sign.toutiaoimg.com/tos-cn-i-axegupay5k/9c18d722ba894c7f87e6b1f25816166a~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=MgR6vpuRQA1HG7wp7G2MrYEDM%2Bo%3D)

雷递网 雷建平 2月8日

Sionna Therapeutics（股票代码为：“SION” ）昨天在美国纳斯达克上市，发行价为18美元，发行1059万股，募资总额为1.9亿美元。

Sionna Therapeutics这笔资金将用于其挑战Vertex Pharmaceuticals 占主导地位的囊性纤维化特许经营权的计划。

Sionna Therapeutics开盘价和收盘价均为25美元，较发行价上涨38.89%；以收盘价计算，公司市值为10.19亿美元。

9个月净亏4584万美元

Sionna Therapeutics成立于2019年，是一家临床阶段生命科学公司，致力于通过使 CFTR（与CF疾病进展相关的关键蛋白）的功能正常化来开发高效和差异化的囊性纤维化 (CF) 治疗方法。

![](https://p9-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/1162ae6912e04a4dbe510b69c7ea1a04~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=CRBf8TRgi2y51oB1lVT%2BWkrqY1g%3D)

Sionna Therapeutics正在推进一系列小分子产品线，这些产品线旨在纠正由 ΔF508（影响 CFTR 蛋白的最常见突变）引起的蛋白质缺陷。该公司拥有一流的项目组合，直接针对 NBD1 的纠正，这是实现完全恢复 ΔF508-CFTR 功能的关键和独特机制，及针对ICL4 和TMD1的补充项目。

招股书显示，Sionna Therapeutics暂无营收，其2022年、2023年运营亏损分别为4137万美元、5033万美元；净亏分别为4024万美元、4726万美元。

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/742c97fb16674117b2f73104ae417620~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=5qrnGgbM7EErOnO21WvB178unrQ%3D)

Sionna Therapeutics在2024年前9个月运营亏损5242万美元，上年同期的运营亏损为3774万美元；净亏损为4584万美元，上年同期的净亏损为3539万美元。

OrbiMed与RA Capital是股东

Sionna Therapeutics在2024年3月曾宣布完成1.82亿美元C轮融资，以推进囊性纤维化新型小分子的临床开发。

Sionna Therapeutics的C轮融资规模扩大且超额认购，由Enavate Sciences领投，新投资者包括 Viking Global Investors 和Perceptive Advisors，RA Capital、OrbiMed、TPG、Atlas Venture、Cystic Fibrosis Foundation、T. Rowe Price Associates等跟投。

IPO前，Atlas Venture持股11.4%，OrbiMed Private Investments VIII持股9.9%，RA Capital持股29.2%，Sionna Aggregator持股为6%；

TPG Growth持股为17.4%，Viking Global Opportunities持股为5.5%，公司CEO、总裁Michael Cloonan,持股为2.9%。

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/8aaec03558b94ad6a50e0fa18633d673~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=zXbFt7Zeb645SS8ZzLimesnFSG0%3D)

IPO后，Atlas Venture持股8.9%，OrbiMed Private Investments VIII持股7.7%，RA Capital持股22.9%，Sionna Aggregator持股为4.7%；

TPG Growth持股为13.6%，Viking Global Opportunities持股为4.3%，公司CEO、总裁Michael Cloonan,持股为2.3%。

以下是Sionna Therapeutics路演PPT（雷递网精编处理）：

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/8c496f1ca2684d6999867ab8b471b1fb~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=t%2B3G%2FYh8cHF7%2By0jQH8nTgLWaQU%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/1b5497198c63407887d002f145059026~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=qlAiNaeLJ5zA6q129O1HO7ONgyo%3D)

![](https://p26-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/a489581fca704a28b5bae587f27da4fc~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=78e7%2F4UI6duc%2FXPqKTNYLbFjzBc%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/2cc108332c5848ec8648768f4921acf1~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=ItSUx1GJyFoO2CRZtg8JoqdOkO0%3D)

![](https://p26-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/fcb0c6a9f7c346169bc34fa43bd12304~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=%2Fo54CQxY8TFVWsdL6ValqH4PK0M%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/975fae92f82e43db87eb52dc525ebd90~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=Ph5y3SvfqBS1aWy%2Br8pqrk3TtjI%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/8aab8cfab68246089e5491c545cd6a43~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=dWL5blMuwW7aEIbQwIBQL8S1Lj8%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/304eaa7b13d84560a364c9689133500e~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=jsmrIUJjA5FbRNCL4YCecRPaML8%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/88f696cb61e14e069061591cda3d1626~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=0NVnWQKsxUc1Gr8vjk7gOzXhig4%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/f56027e9267c4c47bdeab039b37992e4~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=GV5%2FldKGCBVo9qec1oyQiQAF36I%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/051e258b44de44ae96865cf5e0585c13~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=5ivHyuEv5xiH49hY%2Ba7WBrIbuRg%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/4912be2c80a6482d87de59aa3e5ab79f~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=GuT%2BhADEw13v7AxjG%2FkjPnMQ8qM%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/5456fa056a7f4db49ac94c2d168b6a00~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=Jba47S8eIC%2FnqBne4sWviwU%2FkXI%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/15c1ada6e25746dd848beee182d59795~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=MBOmv%2BW0x42dckNUVB8hNQvyEvc%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/36797443666c4f9c872317c5cc94cefa~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=REEaZl8s4vonCc3QmoKTHZVBHMw%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/db63fb06795644838e9d2e90a6e6ad18~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=dNCSDhycakElxup63%2FPwPRzDal8%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/a0a2c9c88566496ea36bc3468c85f796~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=K%2BesT381u9U%2BV9Vdb0GLJeUMzXk%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/25874742b3e744908042ba58ff52b0e9~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=ykTqTJE6Pl0pN%2BWLshq2ueNPm08%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/df2787f6271a4d559331e2968eb3301c~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=QbqcKldQgYUp9mZ8odThjvilUAY%3D)

![](https://p26-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/0410ab1081044b9881deefca6e908f34~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=3B%2FYgsXwnicTkEtHMoCMTUnrOFI%3D)

![](https://p9-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/15f8a0f2461b4637a6e03187e2fef548~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=U6ebkLATvm8Q3GCNmc7z6gDeerQ%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/2d3f8343078c40bc86675e6d5af4b266~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=fInPFheGLXjvogdZlwsKR%2BMmkWw%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/c95300cc00a24dc49a675295a9634ac0~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=6M7okCOhK%2B1VZBbVa2ggTizTJAk%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/4ceca654c9774ba6929f7ee714a764b4~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=euRbIPT2vVRymQOwgsLrgsuC8R8%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/f4321d9c59f8462fb611d763e42c8bc6~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=ZyINblTcHNH8OhOCgr0Of5xPeqI%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/ab0c44d6906e4cc78f74049c5d3d1818~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=e79NzfD9v%2BekNOPMqpmpU7G9UnE%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/2e11b87078f940e3aee0e4584fc912d2~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=%2BeBdKgw7NTalBx0mduxCvwWWLSQ%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/5ad85eae006149c6966e3152962ab343~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=08XoJQGKUVd4ranaS0lIAzTSrnA%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/2941a007713648e291b57a0dd7ceacb2~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=S%2Bh5fD7u2zfNxBT8Mybfl4jJoio%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/0af813f6e9e04a759e9e1ad4af3276c5~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=XLPaWqJ10UWU%2BKigmrTjZXHIEgs%3D)

![](https://p3-sign.toutiaoimg.com/tos-cn-i-6w9my0ksvp/37bac62498704b8f90f3f6124c98ed51~tplv-tt-origin-web:gif.jpeg?_iz=58558&from=article.pc_detail&lk3s=953192f4&x-expires=1739590463&x-signature=RqFre5NCLCKqHMA9kT66Ajx2L3U%3D)

———————————————

[leinews](https://www.leinews.com/n28981/detail.html)
